Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in a global Phase 3 trial for Stargardt ...

Artificial intelligence and machine learning are reshaping how investors build and maintain portfolios. These tools bring ...

Discusses Positive Topline Results from Phase III DRAGON Trial of Tinlarebant in Stargardt Disease December 1, 2025 8:00 ...

Jennifer Simonson is a business journalist with a decade of experience covering entrepreneurship and small business. Drawing on her background as a founder of multiple startups, she writes for Forbes ...